MNG1105
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.318
- HEDGEHOG_SIGNALING+0.308
- WNT_BETA_CATENIN_SIGNALING+0.297
- CHOLESTEROL_HOMEOSTASIS+0.258
- FATTY_ACID_METABOLISM+0.188
- ANGIOGENESIS+0.187
- MYC_TARGETS_V2+0.181
- APICAL_JUNCTION+0.145
- GLYCOLYSIS+0.141
- INTERFERON_ALPHA_RESPONSE+0.141
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.425
- ALLOGRAFT_REJECTION-0.279
- IL6_JAK_STAT3_SIGNALING-0.258
- INFLAMMATORY_RESPONSE-0.245
- MYC_TARGETS_V1-0.236
- PROTEIN_SECRETION-0.211
- TGF_BETA_SIGNALING-0.207
- INTERFERON_GAMMA_RESPONSE-0.187
- PI3K_AKT_MTOR_SIGNALING-0.181
- HYPOXIA-0.162
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 06114a88-396c-4815-8949-910e46345e47 | — | — | 0.659 |
| 2 | MNG457 | — | — | 0.657 |
| 3 | R21 | — | — | 0.655 |
| 4 | SJEPD032_D.RNA-Seq | EPN | Supratentorial EPN | 0.649 |
| 5 | 72c16603-1f6c-479c-8cf0-95d499f328be | — | — | 0.637 |
| 6 | 3698f158-b7ab-4ad0-9064-ee1269a17821 | — | — | 0.628 |
| 7 | MNG142 | — | — | 0.626 |
| 8 | DRR168602 | — | — | 0.619 |
| 9 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.617 |
| 10 | MNG841 | — | — | 0.617 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.318 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.308 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.297 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.258 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.188 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.187 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.181 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.145 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.141 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.141 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.133 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.113 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.079 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.064 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.062 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.054 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.051 | Inavolisib | — uncovered |
| MYOGENESIS | 0.049 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.046 | Inavolisib | — uncovered |